February 13, 2021Open Access

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Blood-based AD biomarker concentrations are associated with pathological and clinical diagnoses and can predict future development of clinical AD, providing evidence that they can be incorporated into multi-ethnic, community-based studies.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Brickman et al. (Sat,) studied this question.

synapsesocial.com/papers/69d90aa3f6b7aa27b79f55af https://doi.org/https://doi.org/10.1002/alz.12301

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinical diagnosis of Alzheimer's disease1984 · 28,003 citations
2From the Help Desk: Comparing Areas under Receiver Operating Characteristic Curves from Two or more Probit or Logit Models2002 · 171 citations
3Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach1988 · 22,419 citations
4Cortical Surface-Based Analysis1999 · 11,512 citations
5Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders2020 · 1,565 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo